The landmark 2023 study that put retatrutide on the map. Here's what actually happened, what the numbers mean, and why researchers are calling it the most potent weight loss compound ever tested.
Research context only. This article summarizes published clinical trial data for educational purposes. Retatrutide is not FDA-approved. All vendor listings on this site are for research use only, not human consumption.
Before retatrutide, the best weight loss results from a drug trial belonged to tirzepatide — roughly 20–21% body weight reduction over 72 weeks in its Phase 3 data. That was already a leap beyond semaglutide's ~15%. Then retatrutide came in and hit 24.2% in 48 weeks — a shorter trial, more weight lost.
To put that in plain terms: a 250-pound person could expect to lose roughly 60 pounds. Not over years. Not with surgery. In under a year, in a controlled trial environment.
The reason retatrutide can do this is its mechanism. While semaglutide hits one receptor (GLP-1) and tirzepatide hits two (GLP-1 and GIP), retatrutide is a triple agonist — it activates GLP-1, GIP, and the glucagon receptor simultaneously. That third receptor, glucagon, is the one that kicks energy expenditure into a higher gear and specifically targets visceral fat.
In plain English: GLP-1 kills your appetite. GIP improves how your body handles insulin. Glucagon tells your fat cells to start burning — especially the deep abdominal fat that's hardest to lose. Hitting all three at once is why the numbers look the way they do.
The Phase 2 trial (NCT04881760) was a randomized, double-blind, placebo-controlled study — the gold standard for clinical research. Participants were adults with a BMI of 30 or higher (or 27+ with at least one weight-related health condition), without type 2 diabetes.
Participants were split into seven groups — six active dose arms and one placebo. The active arms varied by both the maximum dose and how quickly they escalated to it:
All participants received lifestyle counseling alongside the drug. This is standard in obesity trials and makes the drug effect slightly harder to isolate — but the placebo group received the same counseling and lost only about 2% body weight, so the drug effect is clearly the dominant variable.
The headline number — 24.2% — came from the highest dose group (12mg) at week 48. But the full results picture is more nuanced than a single number.
| Dose Group | Mean Weight Loss | % Reaching ≥5% Loss | % Reaching ≥10% Loss |
|---|---|---|---|
| Placebo | ~2.1% | 27% | 10% |
| 1mg | ~8.7% | 75% | 50% |
| 2mg | ~12% | 83% | 67% |
| 4mg | ~17.3% | 91% | 75% |
| 8mg | ~22.8% | 100% | 91% |
| 12mg | 24.2% | 100% | 96% |
A few things worth noting here:
Context check: FDA approval threshold for weight loss drugs is typically ≥5% weight loss vs. placebo. Retatrutide cleared that bar at every dose. The 12mg group cleared it in every single participant.
The trial also tracked metabolic markers, and the results were consistent with what you'd expect from large-scale fat loss:
These secondary findings matter because they suggest retatrutide isn't just moving the number on the scale — it's producing the kind of metabolic improvements that translate to reduced cardiovascular risk.
This is where retatrutide gets complicated. The efficacy numbers are remarkable. The side effect profile is... manageable, but real.
By far the most reported side effects were gastrointestinal — nausea, vomiting, diarrhea, and constipation. This is not surprising; it's the same pattern seen with semaglutide and tirzepatide. The GLP-1 mechanism slows gastric emptying, and your gut takes time to adjust.
About 16% of participants in the highest dose groups discontinued due to adverse events — primarily GI-related. That's higher than the discontinuation rates seen in semaglutide and tirzepatide trials, which likely reflects the more aggressive mechanism.
Worth noting: The 16% discontinuation rate was at the maximum 12mg dose with aggressive titration. The trial was designed to push the compound to its limits. Real-world use with slower titration and lower target doses would likely see lower dropout rates.
One finding that distinguishes retatrutide from the GLP-1 class: a notable increase in resting heart rate, most pronounced at higher doses. This is attributed to the glucagon receptor component. It wasn't clinically dangerous in the trial, but it's being monitored closely in Phase 3, particularly for participants with underlying cardiovascular conditions.
No signals for thyroid tumors or pancreatitis — the two most-watched safety concerns for GLP-1 drugs — emerged in Phase 2. These remain under active surveillance in Phase 3, as they would be for any drug in this class.
Clinical trial data can be deceptive without context. Here's how to read the retatrutide Phase 2 results accurately.
Trial participants were selected, monitored closely, received lifestyle counseling, and had strong compliance incentives. Real-world results with any drug tend to run 20–30% lower than trial results. A 24% Phase 2 result likely translates to something in the 17–20% range in broad clinical use.
That's still exceptional. But managing expectations matters.
Perhaps the most striking finding was that at week 48, participants in the highest dose groups were still losing weight. The curve had not flattened. This is unusual — most GLP-1 drugs show a plateau well before 48 weeks. Phase 3 runs 96 weeks specifically to see where the ceiling actually is.
Eli Lilly launched Phase 3 trials under the TRIUMPH program name. As of 2026, multiple arms are underway:
Phase 3 uses doses up to 12mg weekly with an even more gradual titration schedule than Phase 2 — an attempt to reduce the GI side effect burden and lower the dropout rate. Enrollment targets are in the thousands, far larger than the 338-person Phase 2.
If Phase 3 results hold anywhere near Phase 2, retatrutide would almost certainly become the most prescribed obesity medication in history upon approval. Analysts have projected peak annual sales in the $10–15 billion range.
Expected FDA filing timeline: Eli Lilly has indicated it expects to file a New Drug Application (NDA) based on Phase 3 data in 2026–2027, with potential approval as early as 2027–2028 if trials stay on schedule.
Because retatrutide is not yet FDA-approved, it's currently available only through research chemical suppliers as a lyophilized peptide for laboratory and research purposes. It is not approved for human use.
For researchers and those following the literature, the Phase 2 trial doses provide useful reference points for understanding concentration and dose relationships in the published data:
COA-verified sources with current pricing and promo codes — updated via live price tracking.
View Retatrutide Pricing →